Last updated 4 months ago
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
28 patients around the world
Available in Mexico
Patients in the experimental group will receive two sachets of Glutapak-R every twelve hours for up to six weeks alongside treating physician-chosen EGFR therapy. Patients in the control group will receive a standard-of-care diet.
All patients will receive nutritional counseling every two weeks.
Instituto Nacional de Cancerologia de Mexico
1Research sites
28Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
To 80 Years
All Gender
Medical requirements
- Both sexes≥ 18 years oldPathologically confirmed diagnosis of NSCLCStage IIIB - IV by the American Joint Committee of Cancer Version 8.Candidates to receive EGFR-TKI treatment (1st & 2nd generation TKI)ECOG score ≤ 2Life expectancy > eight weeksSigned written informed consent
- Patients who cannot attend the first protocol appointment.Treatment with other anti-cancer therapyParticipating in other clinical trials in the former four weeksAny other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.Active HIV infection.Breastfeeding.
Sites
Instituto Nacional de Cancerología - Ciudad de México
Recruiting
StudyGlutamine
SponsorInstituto Nacional de Cancerologia de Mexico
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
To 80 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05852990
